DLL4 and neoplasm: PTT with anti-DLL4 conjugated TNPs demonstrated positive therapeutic outcome and tumor growth inhibition similar to SS.BN3IL2Rγ- (DLL4-low) strain (Figure 6). These results confirmed previous preclinical conclusions that vascular targeted NPs increase the efficacy of PTT 57, radiotherapy 58, 59 and delivery of chemotherapeutics to tumor tissues by exerting cytotoxic effects on both endothelial and tumor cells.